Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice
- 31 March 2005
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (5), 799-806
- https://doi.org/10.1016/j.ejca.2005.01.001
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Vascular‐targeting therapies for treatment of malignant diseaseCancer, 2004
- Combretastatin A4 phosphateAnti-Cancer Drugs, 2004
- Antivascular therapy of cancer: DMXAAThe Lancet Oncology, 2003
- Combination of vascular targeting agents with thermal or radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 2002
- The biology of the combretastatins as tumour vascular targeting agentsInternational Journal of Experimental Pathology, 2002
- Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotheraphyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Angiogenesis in cancer and other diseasesNature, 2000
- Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Angiogenesis.Journal of Biological Chemistry, 1992
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989